Clinical trial
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
NCT00347425 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00347425 |
|---|---|
| Title | Switch Study of Existing Atypical Antipsychotics to Bifeprunox |
| Official title | A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Collaborators | H. Lundbeck A/S Industry Wyeth is now a wholly owned subsidiary of Pfizer |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia and Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone |
| Enrollment | 286 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jul 4, 2006 |
| Last update posted | May 21, 2008 |
| Countries | Argentina, Canada, Czechia, Estonia, France, Hungary, Latvia, Lithuania, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: